{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:43:31Z","timestamp":1791211411894,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.drugalcdep.2011.04.013","type":"journal-article","created":{"date-parts":[[2011,5,24]],"date-time":"2011-05-24T03:55:28Z","timestamp":1306209328000},"page":"326-334","source":"Crossref","is-referenced-by-count":41,"title":["Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients"],"prefix":"10.1016","volume":"118","author":[{"given":"Elinore F.","family":"McCance-Katz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Moody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudha","family":"Prathikanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Friedland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petrie M.","family":"Rainey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2011.04.013_bib0005","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0140-6736(10)60829-X","article-title":"Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs","volume":"376","author":"Altice","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.drugalcdep.2011.04.013_bib0010","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1043-6618(05)80021-0","article-title":"Inducing properties of rifabutin, and effects on the pharmacokinetics and metabolism of concomitant drugs","volume":"32","author":"Benedetti","year":"1995","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.drugalcdep.2011.04.013_bib0015","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2165\/00003495-199447060-00008","article-title":"Rifabutin: a review of its antimicrobial activity, pharmacokinentic properties and therapeutic efficacy","volume":"47","author":"Brogden","year":"1994","journal-title":"Drugs"},{"key":"10.1016\/j.drugalcdep.2011.04.013_bib0020","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0376-8716(97)84352-9","article-title":"Lack of a pharmacologic interaction between rifabutin and methadone in HIV-infected former injecting drug users","volume":"43","author":"Brown","year":"1996","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2011.04.013_bib0025","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00003088-200140050-00002","article-title":"Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials","volume":"40","author":"Burman","year":"2001","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.drugalcdep.2011.04.013_bib0030","first-page":"11","article-title":"Prevention and treatment of tuberculosis among patients with human immunodeficiency virus: principles of therapy and revised recommendations","volume":"47","author":"Centers for Disease Control and Prevention","year":"1998","journal-title":"MMWR Recomm. Rep."},{"key":"10.1016\/j.drugalcdep.2011.04.013_bib0035","first-page":"185","article-title":"Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors","volume":"49","author":"Centers for Disease Control and Prevention","year":"2000","journal-title":"MMWR Recomm. Rep."},{"key":"10.1016\/j.drugalcdep.2011.04.013_bib0040","article-title":"Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation","author":"Chang","year":"2010","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.drugalcdep.2011.04.013_bib0045","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1124\/dmd.105.006148","article-title":"Novel metabolites of buprenorphine in human liver microsomes and human urine","volume":"34","author":"Chang","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.drugalcdep.2011.04.013_bib0050","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/187231209788654117","article-title":"Glucuronidation of buprenorphine and norbuprenorphine by human liver microsomes and UDP-glucuronosyltransferases","volume":"3","author":"Chang","year":"2009","journal-title":"Drug Metab. Lett."},{"key":"10.1016\/j.drugalcdep.2011.04.013_bib0055","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0090-9556(25)07765-7","article-title":"The metabolism and excretion of buprenorphine in humans","volume":"12","author":"Cone","year":"1984","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.drugalcdep.2011.04.013_bib0060","first-page":"59","article-title":"Outbreak of multi-drug resistant tuberculosis at a methadone treatment program","volume":"5","author":"Conover","year":"2001","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"10.1016\/j.drugalcdep.2011.04.013_bib0065","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.drugalcdep.2011.04.013_bib0070","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1097\/QAI.0b013e3181f9c0b6","article-title":"Infectious disease comorbidities adversely affecting substance users with HIV: hepatitis C and tuberculosis","volume":"55","author":"Friedland","year":"2010","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.drugalcdep.2011.04.013_bib0075","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1046\/j.1365-2125.1999.00987.x","article-title":"Induction of zidovudine glucuronidation and amidation pathways by rifampicin in HIV-infected patients","volume":"48","author":"Gallicano","year":"1999","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2011.04.013_bib0080","doi-asserted-by":"crossref","first-page":"4928","DOI":"10.1002\/jps.21770","article-title":"Differential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity methadone, buprenorphine, and diprenorphine: in vitro and in vivo evaluation","volume":"98","author":"Hassan","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.drugalcdep.2011.04.013_bib0085","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/01.ftd.0000197094.92559.b4","article-title":"The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry","volume":"28","author":"Huang","year":"2006","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.drugalcdep.2011.04.013_bib0090","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1021\/tx950116m","article-title":"Involvement of cytochrome P450 3A4 enzyme in the n-demethylation of methadone in human liver microsomes","volume":"9","author":"Iribarne","year":"1996","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.drugalcdep.2011.04.013_bib0095","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/S0024-3205(97)00160-4","article-title":"Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes","volume":"60","author":"Iribarne","year":"1997","journal-title":"Life Sci."},{"key":"10.1016\/j.drugalcdep.2011.04.013_bib0100","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJM197605132942008","article-title":"Rifampin-induced methadone withdrawal","volume":"294","author":"Kreek","year":"1976","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drugalcdep.2011.04.013_bib0105","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1046\/j.1360-0443.1998.93454910.x","article-title":"Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine","volume":"93","author":"Kuhlman","year":"1998","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2011.04.013_bib0110","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/BF01733779","article-title":"Pharmacokinetics of oral and intravenous rifampicin during chronic administration","volume":"163","author":"Loos","year":"1985","journal-title":"Klin Wochemschr."},{"key":"10.1016\/j.drugalcdep.2011.04.013_bib0115","doi-asserted-by":"crossref","first-page":"S224","DOI":"10.1086\/508187","article-title":"Interactions between buprenorphine and antiretrovirals I: nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine","volume":"43","author":"McCance-Katz","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.drugalcdep.2011.04.013_bib0120","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.drugalcdep.2007.06.007","article-title":"Interaction between buprenorphine and atazanavir or atazanavir\/ritonavir","volume":"91","author":"McCance-Katz","year":"2007","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2011.04.013_bib0125","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1086\/376907","article-title":"The protease inhibitor lopinavir\/ritonavir may produce opiate withdrawal in methadone-maintained patients","volume":"37","author":"McCance-Katz","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.drugalcdep.2011.04.013_bib0130","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1521-0391.2009.00001.x","article-title":"Effect of cocaine use on buprenorphine pharmacokinetics in humans","volume":"19","author":"McCance-Katz","year":"2010","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.drugalcdep.2011.04.013_bib0135","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1521-0391.2009.00005.x","article-title":"Drug interactions of clinical importance between the opioids, methadone and buprenorphine, and frequently prescribed medications: a review","volume":"19","author":"McCance-Katz","year":"2010","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.drugalcdep.2011.04.013_bib0140","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/10673220490905688","article-title":"Office based treatment of opioid dependence with buprenorphine","volume":"12","author":"McCance-Katz","year":"2004","journal-title":"Harv. Rev. Psychiatry."},{"key":"10.1016\/j.drugalcdep.2011.04.013_bib0145","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1086\/429503","article-title":"Treatment of opioid dependence and HIV\/HCV co-infection in opioid dependent patients: the importance of drug interactions between opioids and antiretroviral medications","volume":"41","author":"McCance-Katz","year":"2005","journal-title":"Clin. Inf. Dis."},{"key":"10.1016\/j.drugalcdep.2011.04.013_bib0150","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1742-7843.2009.00432.x","article-title":"The in vivo response of novel buprenorphine metabolites, M1 and M3, to antiretroviral inducers and inhibitors of buprenorphine metabolism","volume":"105","author":"Moody","year":"2009","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.drugalcdep.2011.04.013_bib0155","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1006\/abio.2002.5673","article-title":"A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a coformulant, naloxone, that is suitable for in vivo and in vitro metabolism studies","volume":"306","author":"Moody","year":"2002","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.drugalcdep.2011.04.013_bib0160","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2165\/00003088-200342090-00003","article-title":"Pharmacokinetic interactions with rifampicin","volume":"42","author":"Nieimi","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.drugalcdep.2011.04.013_bib0165","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/jac\/37.6.1111","article-title":"Inducing properties of rifampicin and rifabutin for selected enzyme activities of the cytochrome P-450 and UDP-glucuronosyltransferase superfamilies in female rat liver","volume":"37","author":"Oesch","year":"1996","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.drugalcdep.2011.04.013_bib0170","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1067\/mcp.2002.128387","article-title":"Cytochrome P450 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin","volume":"72","author":"Paine","year":"2002","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.drugalcdep.2011.04.013_bib0175","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1300\/J069v24n03_04","article-title":"Linkage with methadone treatment upon release from incarceration: a promising opportunity","volume":"24","author":"Rich","year":"2005","journal-title":"J. Addict. Dis."},{"key":"10.1016\/j.drugalcdep.2011.04.013_bib0180","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1128\/AAC.01749-09","article-title":"Pharmacokinetics of darunavir\/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers","volume":"54","author":"Sekar","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drugalcdep.2011.04.013_bib0185","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/QCO.0b013e3283210020","article-title":"Multidrug-resistant and extensively drug-resistant tuberculosis: consequences for the global HIV community","volume":"22","author":"Shenoi","year":"2009","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.drugalcdep.2011.04.013_bib0190","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1128\/AAC.33.8.1237","article-title":"Pharmacokinetics of rifabutin","volume":"33","author":"Skinner","year":"1989","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drugalcdep.2011.04.013_bib0195","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/ALN.0b013e3181642938","article-title":"Role of CYP 2B6 in human methadone metabolism","volume":"108","author":"Totah","year":"2008","journal-title":"Anesthesiology"},{"key":"10.1016\/j.drugalcdep.2011.04.013_bib0200","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/02791072.2006.10399844","article-title":"Case-control, retrospective study of pulmonary tuberculosis in heroin abusing patients in China","volume":"38","author":"Wang","year":"2006","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.drugalcdep.2011.04.013_bib0205","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/02791072.2003.10400007","article-title":"The clinical opiate withdrawal scale (COWS)","volume":"35","author":"Wesson","year":"2003","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.drugalcdep.2011.04.013_bib0210","unstructured":"World Health Organization, 2010. Global Tuberculosis Control. WHO Rep. Geneva."},{"key":"10.1016\/j.drugalcdep.2011.04.013_bib0215","unstructured":"World Health Organization, 2008. Policy guidelines for collaborative TB and HIV services for injecting and other drug users: an integrated approach. WHO Rep. Geneva."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871611001700?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871611001700?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T19:37:17Z","timestamp":1741203437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871611001700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":43,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0376871611001700"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2011.04.013","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}